Effects of YM087 and VPA985 on the T237M mutant receptor functionality in nephrogenic diabetes insipidus-Reference-Cited by-同舟云学术

Effects of YM087 and VPA985 on the T237M mutant receptor functionality in nephrogenic diabetes insipidus

Published:2024-08-20 Issue: Volume: Page:
ISSN:1303-829X
Container-title:Turkish Journal of Biochemistry
language:en
Short-container-title:

Author:

Avcu Elif Merve¹^ORCID,Erdem Tuncdemir Beril¹^ORCID,Saglar Ozer Emel¹^ORCID

Affiliation:

1. Department of Biology, Faculty of Science , Hacettepe University , Ankara , Türkiye

Abstract

Abstract Objectives Mutations detected in the AVPR2 gene (arginine vasopressin type 2 receptor) are known to cause nephrogenic diabetes insipidus (NDI). Several pharmacological chaperones (PCs) target misfolded AVPR2 proteins and rescue them from the quality control system of the cell. In this study, we investigated the effect of YM087 and VPA985, which are PCs, on T273M-AVPR2 mutant that are known to cause NDI. Methods The total and cell surface expressions of T273M in COS-1 cells were measured by sandwich ELISA and flow cytometry after the cells were treated with YM087 and VPA985 separately. In addition, the cAMP accumulation assay was performed. Results It was observed that VPA985 treatment significantly increased the cell surface expression and slightly increased the maximum cAMP response of T273M. Both YM087 and VPA985 decreased the ligand concentrations which were responsible for making half of the maximum response of the T273M mutant receptor. Conclusions PCs have different potential effects on different AVPR2 mutants. Therefore, studying the effectiveness of PCs in rescuing AVPR2 mutants and making them functional again may contribute to the development of new therapeutic strategies.

Funder

Hacettepe University

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/tjb-2024-0024/pdf

Reference26 articles.

1. Broadley, SA, Hartl, FU. The role of molecular chaperones in human misfolding diseases. FEBS Lett 2009;583:2647–53. https://doi.org/10.1016/j.febslet.2009.04.029.

2. Wootten, D, Christopoulos, A, Marti-Solano, M, Babu, MM, Sexton, PM. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol 2018;19:638–53. https://doi.org/10.1038/s41580-018-0049-3.

3. Vassart, G, Costagliola, S. G protein-coupled receptors: mutations and endocrine diseases. Nat Rev Endocrinol 2011;7:362–72. https://doi.org/10.1038/nrendo.2011.20.

4. Schöneberg, T, Liebscher, I. Mutations in G protein–coupled receptors: mechanisms, pathophysiology and potential therapeutic approaches. Pharmacol Rev 2021;73:89–119. https://doi.org/10.1124/pharmrev.120.000011.

5. Robben, JH, Knoers, NVAM, Deen, PMT. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. Am J Physiol Ren Physiol 2005;289:265–72. https://doi.org/10.1152/ajprenal.00404.2004.